Education
About Us
Working with TipRanks
Follow Us
Pfizer (GB:0Q1N)
LSE:0Q1N
0Q1N Stock Chart & Stats
$27.47
-$0.50(-1.83%)
At close: 4:00 PM EST
$27.47
-$0.50(-1.83%)
Day’s Range― - ―
52-Week Range$20.77 - $28.00
Previous CloseN/A
Volume69.09K
Average Volume (3M)111.80K
Market Cap
$157.23B
Enterprise Value$218.65B
Total Cash (Recent Filing)$13.60B
Total Debt (Recent Filing)$64.80B
Price to Earnings (P/E)20.3
Beta0.96
Next Earnings
May 05, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding5,686,267,600
10 Day Avg. Volume71,902
30 Day Avg. Volume111,804
Financial Highlights & Ratios
PEG Ratio-4.31
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue3.49
Enterprise Value/Gross Profit4.97
Enterprise Value/Ebitda14.48
Forecast
1Y Price Target
$28.78Price Target Upside4.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)2.96
Revenue Forecast (FY)$61.18B
Bulls Say, Bears Say
Bulls Say
Commercial Performance And Margin ImprovementStronger-than-expected commercial results, supported by vaccine and specialty product sales along with improved gross and operating margins from cost efficiencies, bolster earnings and free cash for strategic initiatives.
Obesity Portfolio ExpansionMetsera acquisition brings a monthly fixed‑dose GLP‑1 and amylin combination that can serve as a central product in the obesity portfolio, expanding treatment options and addressing diverse patient needs.
Oncology Clinical CatalystSigvotatug vedotin showed long responses in earlier studies, so a positive Phase 3 lung cancer outcome could become a major value catalyst for the oncology franchise.
Bears Say
Capacity Constraints For Pipeline ExpansionBalancing commitments to multiple major clinical programs with limited capacity to add new development projects may force prioritization and raise execution risk if key trials encounter delays or setbacks.
Clinical Data UncertaintyQuestions about placebo effects and study discontinuation in topline obesity data create uncertainty until the full dataset and detailed analyses are available.
Revenue Erosion And Product SoftnessRevenue risk from products facing loss of exclusivity, combined with softer sales in key medicines such as the oral antiviral and certain oncology therapies, could pressure top-line growth.
Pfizer News
0Q1N FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest share price was $20.77 and its highest was $28.00 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $157.23B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is May 05, 2026 which is in 63 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Feb 03, 2026. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.567 by $0.093.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer does not currently pay dividends.
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.73.
How many shares outstanding does Pfizer have?
Pfizer has 5,686,267,600 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.66 in its last earnings report, beating expectations of $0.567. Following the earnings report the stock price went down -2.872%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in GB:0Q1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.78 (4.77% Upside)
$28.78 (4.77% Upside)
Blogger Sentiment
Bullish
GB:0Q1N Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.63%
12-Months-Change
Fundamentals
Return on Equity
8.87%
Trailing 12-Months
Asset Growth
-2.45%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
0Q1N Company Deck
0Q1N Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positives — better‑than‑expected adjusted EPS, margin expansion, meaningful cost‑savings realization, promising obesity (PF‑3944) clinical readouts with differentiated monthly dosing, robust activity on pivotal studies and approvals, and strategic acquisitions that are already contributing revenue growth. Offsetting these strengths are near‑term challenges: modest overall revenue decline (driven largely by a pronounced COVID revenue drop), a sizable $4.4 billion impairment reflecting portfolio reprioritization, upcoming LOE pressure (including ~ $1.5 billion revenue compression projected in 2026), and some GAAP volatility in the quarter. On balance, the company reinforced a clear strategic plan, reaffirmed 2026 guidance, and emphasized productivity/AI initiatives and reinvestment into high‑impact R&D, suggesting the positives materially outweigh the near‑term negatives.View all GB:0Q1N earnings summaries0Q1N Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
0Q1N Stock 12 Month Forecast
Average Price Target
$28.78
▲(4.77% Upside)
Technical Analysis
Options Prices
Currently, No data available
---